+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 15 Actively Recruiting clinical trials

L

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.

Age: 18Years - 79YearsAll GendersPhase 3
74 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as an add-on treatment for adolescents and adults with Type 2 asthma who are at risk of flare-ups. The study compares depemokimab plus standard care with a placebo plus standard care to assess the effect on asthma exacerbations and other health outcomes. This Phase 3b4 trial is designed to understand how early intervention with depemokimab impacts lung function, asthma control, and safety over up to 156 weeks. Participants are randomly assigned to receive either depemokimab or a placebo, both alongside their usual asthma treatment. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given. Treatment and assessments occur over about three years with regular monitoring of lung function and asthma symptoms. The trial includes a detailed evaluation of quality of life and asthma control scores at baseline and after two years. Participants will be involved in regular visits for lung function tests and questionnaires about their asthma control and quality of life. Researchers will track the annual rate of significant asthma exacerbations, improvements in clinical remission, and changes in lung function. Safety and adherence to treatment are also monitored throughout the study. The entire participation can last up to 156 weeks, with ongoing assessments to evaluate how the study drug affects participants asthma.

Age: 12Years +All GendersPhase 3
17 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of Tradipitant on treating nausea and vomiting caused by GLP-1 receptor agonist use in adults who are overweight or have class I or II obesity. This phase 3, randomized, placebo-controlled study includes healthy volunteers without serious medical issues or diabetes. The goal is to better understand how Tradipitant impacts these symptoms compared to a placebo. Participants will be randomly assigned to receive either Tradipitant or a placebo, both given as oral capsules twice daily for about two weeks. The study has two treatment arms one receiving Tradipitant and the other receiving a placebo. The study uses quadruple masking to ensure unbiased results. During the study, participants will record nausea and vomiting symptoms daily in a symptom diary. Researchers will measure the proportion of participants experiencing vomiting episodes and assess nausea severity over one week. The study will monitor safety and side effects throughout, with the total participation duration around two weeks of treatment.

Age: 18Years - 65YearsAll GendersPhase 3
10 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy improves invasive breast cancer-free survival in premenopausal women with early-stage estrogen receptor-positive, HER2-negative breast cancer and specific recurrence scores. This Phase III trial addresses a critical need for better treatment options in younger women, who face higher risks of breast cancer recurrence and mortality. Participants will receive one of two treatment approaches ovarian function suppression combined with an aromatase inhibitor for five years, or chemotherapy followed by the same hormonal treatment. The choice of chemotherapy, aromatase inhibitor, and ovarian suppression method is determined by the investigator, with options such as goserelin, leuprolide, or triptorelin administered monthly or every three months. Endocrine therapy beyond five years is at the investigators discretion, and bilateral oophorectomy may replace ovarian suppression if desired. During the trial, participants will be monitored for invasive breast cancer-free survival over 11 years following randomization. Additional outcomes include overall survival, disease-free survival, distant recurrence, and treatment-related symptoms such as menopausal effects and pain during aromatase inhibitor therapy. The study involves regular assessments to evaluate these outcomes and ensure participant safety throughout the extended follow-up period.

Age: 18Years - 60YearsFEMALEPhase 3
1276 locations
R

Actively Recruiting

Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.

Age: 12Years - 17YearsAll GendersPhase 3
155 locations
S

Actively Recruiting

This clinical trial is investigating iloperidone as a potential treatment for people with uncontrolled hypertension, a condition where blood pressure remains high despite treatment. The study is designed as a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial to evaluate both the effectiveness and safety of iloperidone for this condition. Participants will be randomly assigned to receive either iloperidone or a placebo. The study involves careful monitoring over a treatment period of 4 weeks to assess changes in systolic blood pressure. Both the experimental drug and placebo are given under controlled conditions, and neither the participants nor the researchers know who receives which. During the study, participants systolic blood pressure will be measured from baseline through week 4 to evaluate treatment response. Safety and any side effects will be monitored closely. The total study duration includes initial screening followed by the 4-week treatment period. Participants will have regular visits for blood pressure measurements and health assessments throughout the trial.

Age: 18Years - 65YearsAll GendersPhase 2
28 locations
L

Actively Recruiting

Researchers are studying the long-term effects of maridebart cafraglutide in adults with obesity or overweight who also have type 2 diabetes. This Phase 3 trial aims to evaluate how well the drug works, its safety, and how well participants tolerate it over time. The trial is an extension of a previous study, allowing continued assessment of the treatments impact over a longer period. Participants receive different doses of maridebart cafraglutide or placebo, administered as injections under the skin. Those who had low doses in the previous study continue with the same low dose every 4 weeks. Participants who had medium or high doses in the earlier trial may be randomly assigned to continue their dose every 4 or 8 weeks, or receive placebo injections every 4 weeks. Some participants who previously received placebo will start a high dose with a gradual increase before reaching the full dose. During the study, participants will have regular visits for up to 48 weeks to monitor body weight changes, blood sugar control, waist size, and quality of life. Researchers will carefully track any side effects or serious health events throughout the treatment. The study runs until March 2028, providing detailed information on the long-term use of maridebart cafraglutide.

Age: 18Years - 99YearsAll GendersPhase 3
45 locations
C

Actively Recruiting

Researchers are studying colorectal cancer incidence in people aged 45 to 70 who have 1 to 2 small, non-advanced adenomas found on colonoscopy. The trial compares two surveillance strategies performing follow-up colonoscopies at both 5 and 10 years versus only at 10 years. The goal is to better understand the timing and benefit of surveillance colonoscopy for this common condition, as current guidelines vary and lack strong randomized evidence. Participants are randomly assigned to receive either a surveillance colonoscopy at 5 and 10 years or at 10 years only after their qualifying colonoscopy. The colonoscopies will follow current quality guidelines, with all polyps completely removed during the initial exam. Standard preparation instructions will be given before each colonoscopy. This study aims to provide clear evidence on the best interval for surveillance after detecting non-advanced adenomas. During the study, participants will be monitored for colorectal cancer development over 10 years, which is the primary outcome measure. Follow-up includes scheduled colonoscopies and any necessary unscheduled procedures according to clinical need. The study will collect data on cancer incidence to guide future clinical recommendations. Participants will be followed until the study ends with safety and health closely observed throughout their participation.

Age: 45Years - 70YearsAll GendersPhase Not Applicable
499 locations
S

Actively Recruiting

Researchers are studying type 2 diabetes, a condition where the body cannot properly use insulin to control blood sugar, leading to complications like heart disease, kidney failure, and nerve damage. This research evaluates a botanical extract called HP-211, which has shown promise in lab and animal studies for helping insulin work better to lower blood sugar and insulin levels. The goal is to see if HP-211 can reduce blood glucose and insulin responses in people with type 2 diabetes, especially those with insulin resistance. Participants will be randomly assigned to receive different doses of HP-2110.98 grams, 1.96 grams, or 2.94 grams twice dailyor a placebo, taken as tablets in the morning and evening for 90 days, preferably at least 60 minutes before meals. The study includes a dose-ranging phase to test safety and proof of concept by comparing these doses. Researchers will monitor changes in blood sugar control and insulin levels during the treatment period. Throughout the trial, participants will have blood tests to measure hemoglobin A1c HbA1c, which reflects average blood sugar over time, as well as fasting blood glucose and self-monitored blood glucose profiles. Safety assessments will track adverse events, body weight, and quality of life related to diabetes treatment. The study lasts 12 weeks of treatment plus 4 weeks of withdrawal monitoring, with ongoing evaluations to assess the effects and safety of HP-211 on blood sugar control.

Age: 18Years +All GendersPhase 2
25 locations

1-10 of 15

1